XVIR
DEAD

Serial Number

78555670

Owner

XVir Therapeutics GmbH

Attorney

Matthew J. Smith

Filing Date

Jan 28, 2005

Add to watchlist:

No watchlists yet
View on USPTO

XVIR Trademark

Serial Number: 78555670 • Registration: 3385323

XVIR is a trademark filed by XVir Therapeutics GmbH on January 28, 2005. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

XVir Therapeutics GmbH (5 trademarks)

Nymphenburger Str. 1
Munich D080335 , DE

Entity Type: 16

Trademark Details

Filing Date

January 28, 2005

Registration Date

February 19, 2008

Published for Opposition

October 10, 2006

Cancellation Date

September 26, 2014

Goods & Services

Scientific laboratory equipment, namely, photometers, mass spectrometers, ELISA readers, positron emission tomography (PET) scanners, thermocyclers, nuclear magnetic resonance (NMR) spectrometers, fluorescence-activated cell sorters, cell counters, and blotting devices using electric, magnetic, or capillary forces for material transfer

Chemical products for medical and veterinary clinical use, namely nucleic acids, vectors, plasmids, viruses, peptides and proteins, lipids, lipid coated proteins, lipid coated nucleic acids, lipid coated viruses, lipid coated vectors, lipid coated plasmids, antibodies, anticalines, aptamers, spiegelmers, siRNA molecules, antisense oligonucleotides, ribosomes, decoy oligonucleotides; Pharmaceutical and veterinary preparations, namely slimming agents, appetite suppressants, acidosis therapeutics, analeptics, antihypoximics, analgesics, antirheumatic drugs, antihelmintics, antiallergics, anti-anemia drugs, antiarrhythmics, antibiotics, anti-infective agents, antidementics, nootropics, antidiabetics, antidotes, antiemetics, antivertiginosics, antiepileptics, antihemorrhagics, antifibrinolytics, hemostatics, antihypertonics, antihypoglycemics, antihypotonics, anticoagulants, antimycotics, antiparasitic agents, antiphlogistics, expectorants, agents for use in atherosclerosis, balneotherapeutics and preparations for heat therapy, beta receptor blocking agents, calcium channel blocking agents and inhibitors of the renin-angiotensin-system, broncholytics, antiasthmetics, cholagoguegics and biliary tract therapeutics, cholinergics, corticoids, dermatics, general purpose disinfectants, antiseptics, dietetic foods adapted for medical use, alimentary therapeutics, diagnostic preparations for medical and veterinary use, diuretics, preparations for the stimulation of blood circulation, fibrinolytics, geriatric agents for the treatment of stress and age-related diseases, geriatric nutritional supplements, agents for use in gout, agents for use in flu and in catarrhal fever, gynecological agents, hemorrhoid agents, hepatics, hypnotics, sedatives, cardiac therapeutics, agents for removal of dental stain, agents for reconstitution of gums, materials for dental fillings and for dental sealing purposes, corona agents, laxatives, antilipaemics, local anesthetics, neural therapeutics, gastro-intestinal agents, migraine agents, mineral supplements, mouth and pharyngeal therapeutics, muscle relaxants, narcotics, neuropathical agents and other neurotropic agents, ophthalmic preparations, agents for use in osteoporosis, calcium metabolism modifying agents, agents for use in Parkinson's Disease and other agents against disturbances of the extrapyramidal system, psychotropic agents, rhinologics, sinositic agents, roborants, thyroidal therapeutics, spasmolytics, inhibitors of thrombocyte aggregation, tuberculosis agents, altemants, urologics, venous agents, vitamins, cytostatics and other antineoplastic agents and protectives, homeopathic supplements; and Pharmaceutical and veterinary preparations in the nature of viruses, viruses for oncolysis, viruses for gene therapy, viruses for delivery of pharmaceutically active compounds, viruses for restoration of drug sensitivity, viruses for restoration of apoptosis, and viruses for cancer therapy, all for clinical use

Chemical products for research use and for use in the manufacture of pharmaceuticals, namely nucleic acids, vectors, plasmids, viruses, peptides and proteins, lipids, lipid coated proteins, lipid coated nucleic acids, lipid coated viruses, lipid coated vectors, lipid coated plasmids, antibodies, anticalines, aptamers, aptamers consisting essentially of L-nucleotides, short limiting RNA molecules without specific limitation to the number of nucleotides, antisense oligonucleotides, ribozymes, decoy oligonucleotides

Medical services featuring physicians and surgeons; veterinary services; medical services, namely, determination of individual disease risk, determination of individual cancer therapy, identifying patient groups treatable by oncolytic viruses, individual health care and managed health care services

Scientific and medical research services in biology, molecular biology, chemistry, biochemistry, genetics, molecular genetics, and pathology; scientific and medical research services for third parties, namely, determination of viral particles, determination and sequencing of viral genome, determination of nuclear YB-1 binding protein, determination of drug resistance in samples, determination of radiation resistance in samples, design of viral vectors, design of plasmid vectors, design of viruses and in particular oncolytic viruses; scientific and medical research services, namely, design and performance of clinical trials

Filing History

CANCELLED SEC. 8 (6-YR)
Sep 26, 2014 C8..
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 22, 2011 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 3, 2010 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 3, 2010 REAP
REGISTERED-PRINCIPAL REGISTER
Feb 19, 2008 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Jan 11, 2008 DP1B
NOTICE OF ALLOWANCE CANCELLED
Dec 28, 2007 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Dec 28, 2007 D1BR
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 15, 2007 CHAN
PAPER RECEIVED
Oct 25, 2007 MAIL
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 29, 2007 TCCA
SOU EXTENSION 1 GRANTED
Jun 29, 2007 EX1G
SOU EXTENSION 1 FILED
Jun 29, 2007 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 29, 2007 EEXT
NOA MAILED - SOU REQUIRED FROM APPLICANT
Jan 2, 2007 NOAM
ASSIGNED TO EXAMINER
Oct 12, 2006 DOCK
PUBLISHED FOR OPPOSITION
Oct 10, 2006 PUBO
NOTICE OF PUBLICATION
Sep 20, 2006 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 18, 2006 PREV
ASSIGNED TO LIE
Aug 11, 2006 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 3, 2006 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 3, 2006 XAEC
EXAMINERS AMENDMENT E-MAILED
Aug 3, 2006 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 3, 2006 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Aug 3, 2006 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Jul 10, 2006 PBCR
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jun 16, 2006 PREV
ASSIGNED TO LIE
Jun 2, 2006 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
May 31, 2006 CNSA
EXAMINER'S AMENDMENT ENTERED
May 31, 2006 XAEC
EXAMINERS AMENDMENT E-MAILED
May 31, 2006 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 31, 2006 CNEA
FINAL REFUSAL E-MAILED
Dec 7, 2005 GNFR
FINAL REFUSAL WRITTEN
Dec 7, 2005 CNFR
AMENDMENT FROM APPLICANT ENTERED
Dec 5, 2005 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 21, 2005 CRFA
PAPER RECEIVED
Oct 21, 2005 MAIL
AMENDMENT FROM APPLICANT ENTERED
Oct 14, 2005 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 4, 2005 CRFA
PAPER RECEIVED
Oct 4, 2005 MAIL
PRIORITY ACTION E-MAILED
Aug 31, 2005 GPRA
PRIORITY ACTION WRITTEN
Aug 31, 2005 CPRA
ASSIGNED TO EXAMINER
Aug 26, 2005 DOCK
NEW APPLICATION ENTERED
Feb 7, 2005 NWAP
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Jan 31, 2005 AMPX
PAPER RECEIVED
Jan 31, 2005 MAIL